Dopamine genes and nicotine dependence in treatment-seeking and community smokers

Neuropsychopharmacology

Volumn 34, Issue 10, 2009, Pages 2252-2264

  Bergen, Andrew W ^a   Conti, David V ^b   Van Den Berg, David ^b   Lee, Wonho ^b   Liu, Jinghua ^b   Li, Dalin ^b   Guo, Nan ^a   Mi, Huaiyu ^a   Thomas, Paul D ^a   Lessov Schlaggar, Christina N ^c   Krasnow, Ruth ^a   He, Yungang ^a   Nishita, Denise ^a   Jiang, Ruhong ^a   McClure, Jennifer B ^d   Tildesley, Elizabeth ^e   Hops, Hyman ^e   Tyndale, Rachel F ^f,g   Benowitz, Neal L ^h   Lerman, Caryn ⁱ   Swan, Gary E ^a   more..

^a SRI INTERNATIONAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d CENTER FOR HEALTH STUDIES   (United States)

^e OREGON RESEARCH INSTITUTE   (United States)

^f CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Candidate gene; Dopamine transporter; Fagerstr m Test for Nicotine Dependence; Gene gene interaction; Single nucleotide polymorphism

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER; NICOTINE; NICOTINIC RECEPTOR;

AGE; ARTICLE; BIOINFORMATICS; COHORT ANALYSIS; DEPRESSION; DOPAMINERGIC SYSTEM; EDUCATION; FAGERSTROM TEST FOR NICOTINE DEPENDENCE; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; HELP SEEKING BEHAVIOR; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEPTOR DENSITY; SEX; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TOBACCO DEPENDENCE;

ADULT; ANALYSIS OF VARIANCE; BUPROPION; COHORT STUDIES; DNA-BINDING PROTEINS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, DOPAMINE D3; RESIDENCE CHARACTERISTICS; SMOKING; TOBACCO USE DISORDER; TRANSCRIPTION FACTORS;

EID: 68949170833     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.52     Document Type: Article

References (99)

1. Agrawal A, Pergadia ML, Saccone SF, Hinrichs AL, Lessov-Schlaggar CN, Saccone NL et al (2008). Gamma-aminobutyric acid receptor genes and nicotine dependence: evidence for association from a case-control study. Addiction 103: 1027-1038.
2. Audrain-McGovern J, Lerman C, Wileyto EP, Rodriguez D, Shields PG (2004). Interacting effects of genetic predisposition and depression on adolescent smoking progression. Am J Psychiatry 161: 1224-1230.
3. Bannon MJ, Pruetz B, Manning-Bog AB, Whitty CJ, Michelhaugh SK, Sacchetti P et al (2002). Decreased expression of the transcription factor NURR1 in dopamine neurons of cocaine abusers. Proc Natl Acad Sci USA 99: 6382-6385.
4. Barrett JC, Fry B, Maller J, Daly MJ (2005). Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
5. Benowitz NL (2008). Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther 83: 531-541.
6. Berrettini W, Yuan X, Tozzi F, Song K, Francks C, Chilcoat H et al (2008). Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psychiatry 13: 368-373.
7. Beuten J, Ma JZ, Payne TJ, Dupont RT, Crews KM, Somes G et al (2005). Single- and multilocus allelic variants within the GABA(B) receptor subunit 2 (GABAB2) gene are significantly associated with nicotine dependence. Am J Hum Genet 76: 859-864.
8. Bierut LJ, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau OF et al (2007). Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum Mol Genet 16: 24-35.
9. Bonci A, Hopf FW (2005). The dopamine D2 receptor: new surprises from an old friend. Neuron 47: 335-338.
10. Brody AL, Mandelkern MA, Olmstead RE, Scheibal D, Hahn E, Shiraga S et al (2006). Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. Arch Gen Psychiatry 63: 808-816.
11. Broms U, Madden PA, Heath AC, Pergadia ML, Shiffman S, Kaprio J (2007). The nicotine dependence syndrome scale in Finnish smokers. Drug Alcohol Depend 89: 42-51.
12. Brookes KJ, Neale BM, Sugden K, Khan N, Asherson P, D'Souza UM (2007). Relationship between VNTR polymorphisms of the human dopamine transporter gene and expression in post-mortem midbrain tissue. Am J Med Genet B Neuropsychiatr Genet 144B: 1070-1078.
13. Caporaso N, Gu F, Chatterjee N, Sheng-Chih J, Yu K, Yeager M et al (2009). Genome-wide and candidate gene association study of cigarette smoking behaviors. PLoS ONE 4: e4653.
14. CDC (2003). Cigarette smoking-attributable morbidity - United States, 2000. MMWR Morb Mortal Wkly Rep 52: 842-844.
15. Conneely KN, Boehnke M (2007). So many correlated tests, so little time! rapid adjustment of P-values for multiple correlated tests. Am J Hum Genet 81: 1158-1168.
16. Conti DV, Lee W, Li D, Liu J, Van Den Berg D, Thomas PD et al (2008). Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum Mol Genet 17: 2834-2848.
17. Cossette M, Levesque D, Parent A (2005). Neurochemical characterization of dopaminergic neurons in human striatum. Parkinsonism Relat Disord 11: 277-286.
18. David SP, Brown RA, Papandonatos GD, Kahler CW, Lloyd-Richardson EE, Munafo MR et al (2007). Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res 9: 821-833.
19. David SP, Munafo MR (2008). Genetic variation in the dopamine pathway and smoking cessation. Pharmacogenomics 9: 1307-1321.
20. Drgon T, Lin Z, Wang GJ, Fowler J, Pablo J, Mash DC et al (2006). Common human 50 dopamine transporter (SLC6A3) haplotypes yield varying expression levels in vivo. Cell Mol Neurobiol 26: 875-889.
21. Erblich J, Lerman C, Self DW, Diaz GA, Bovbjerg DH (2004). Stress-induced cigarette craving: effects of the DRD2 TaqI RFLP and SLC6A3 VNTR polymorphisms. Pharmacogenomics J 4: 102-109.
22. Erblich J, Lerman C, Self DW, Diaz GA, Bovbjerg DH (2005). Effects of dopamine D2 receptor (DRD2) and transporter (SLC6A3) polymorphisms on smoking cue-induced cigarette craving among African-American smokers. Mol Psychiatry 10: 407-414.
23. Ezzati M, Lopez AD (2003). Estimates of global mortality attributable to smoking in 2000. Lancet 362: 847-852.
24. Fagerström KO (1978). Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 3: 235-241.
25. Franklin TR, Lohoff FW, Wang Z, Sciortino N, Harper D, Li Y et al (2008). DAT genotype modulates brain and behavioral responses elicited by cigarette cues. Neuropsychopharmacology 34: 717-728.
26. Gauderman WJ (2002). Sample size requirements for association studies of gene-gene interaction. Am J Epidemiol 155: 478-484.
27. Gelernter J, Yu Y, Weiss R, Brady K, Panhuysen C, Yang BZ et al (2006). Haplotype spanning TTC12 and ANKK1, flanked by the DRD2 and NCAM1 loci, is strongly associated to nicotine dependence in two distinct American populations. Hum Mol Genet 15: 3498-3507.
28. Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA et al (2007). The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 81: 328-345.
29. Goldman D, Bergen A (1998). General and specific inheritance of substance abuse and alcoholism. Arch Gen Psychiatry 55: 964-965.
30. Greenwood TA, Kelsoe JR (2003). Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene. Genomics 82: 511-520.
31. Han DH, Joe KH, Na C, Lee YS (2008). Effect of genetic polymorphisms on smoking cessation: a trial of bupropion in Korean male smokers. Psychiatr Genet 18: 11-16.
32. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO (1991). The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. Br J Addict 86: 1119-1127.
33. Heatherton TF, Kozlowski LT, Frecker RC, Rickert W, Robinson J (1989). Measuring the heaviness of smoking: using self-reported time to the first cigarette of the day and number of cigarettes smoked per day. Br J Addict 84: 791-799.
34. Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, Gorey JG et al (2000). Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 22: 133-139.
35. Hinrichs AS, Karolchik D, Baertsch R, Barber GP, Bejerano G, Clawson H et al (2006). The UCSC genome browser database: update 2006. Nucleic Acids Res 34: D590-D598.
36. Hops H, Andrews JA, Duncan SC, Duncan TE, Tildesley E (2000). Adolescent drug use development, a social interactional and contextual perspective. In: Arnold J, Sameroff ML, Miller SM (eds). Handbook of Developmental Psychopathology, 2nd edn. Kluwer Academic/Plenum Publishers: New York. pp 589-605.
37. Horvath MC, Kovacs GG, Kovari V, Majtenyi K, Hurd YL, Keller E (2007). Heroin abuse is characterized by discrete mesolimbic dopamine and opioid abnormalities and exaggerated nuclear receptor-related 1 transcriptional decline with age. J Neurosci 27: 13371-13375.
38. Huang W, Payne TJ, Ma JZ, Beuten J, Dupont RT, Inohara N et al (2008). Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample. Neuropsychopharmacology 34: 319-330.
39. Hudmon KS, Marks JL, Pomerleau CS, Bolt DM, Brigham J, Swan GE (2003). A multidimensional model for characterizing tobacco dependence. Nicotine Tob Res 5: 655-664.
40. International HapMap Consortium (2005). A haplotype map of the human genome. Nature 437: 1299-1320.
41. Ishiguro H, Okubo Y, Ohtsuki T, Yamakawa-Kobayashi K, Arinami T (2002). Mutation analysis of the retinoid X receptor beta, nuclear-related receptor 1, and peroxisome proliferator-activated receptor alpha genes in schizophrenia and alcohol dependence: possible haplotype association of nuclear-related receptor 1 gene to alcohol dependence. Am J Med Genet 114: 15-23.
42. Jankovic J, Chen S, Le WD (2005). The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol 77: 128-138.
43. Jorm AF, Henderson AS, Jacomb PA, Christensen H, Korten AE, Rodgers B et al (2000). Association of smoking and personality with a polymorphism of the dopamine transporter gene: results from a community survey. Am J Med Genet 96: 331-334.
44. Kelada SN, Costa-Mallen P, Checkoway H, Carlson CS, Weller TS, Swanson PD et al (2005). Dopamine transporter (SLC6A3) 50 region haplotypes significantly affect transcriptional activity in vitro but are not associated with Parkinson's disease. Pharmacogenet Genomics 15: 659-668.
45. Kilmer G, Roberts H, Hughes E, Li Y, Valluru B, Fan A et al (2008). Surveillance of certain health behaviors and conditions among states and selected local areas - Behavioral Risk Factor Surveillance System (BRFSS), United States, 2006. MMWR Surveill Summ 57: 1-188.
46. Laucht M, Becker K, Frank J, Schmidt MH, Esser G, Treutlein J et al (2008). Genetic variation in dopamine pathways differentially associated with smoking progression in adolescence. J Am Acad Child Adolesc Psychiatry 47: 673-681.
47. Law SW, Conneely OM, DeMayo FJ, O'Malley BW (1992). Identification of a new brain-specific transcription factor, NURR1. Mol Endocrinol 6: 2129-2135.
48. Lerman C, Caporaso NE, Audrain J, Main D, Bowman ED, Lockshin B et al (1999). Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 18: 14-20.
49. Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F et al (2006). Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 31: 231-242.
50. Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk Jr LH, Pinto A et al (2003). Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 22: 541-548.
51. Li MD (2008). Identifying susceptibility loci for nicotine dependence: 2008 update based on recent genome-wide linkage analyses. Hum Genet 123: 119-131.
52. Li MD, Burmeister M (2009). New insights into the genetics of addiction. Nat Rev Genet 10: 225-231.
53. Ling D, Niu T, Feng Y, Xing H, Xu X (2004). Association between polymorphism of the dopamine transporter gene and early smoking onset: an interaction risk on nicotine dependence. J Hum Genet 49: 35-39.
54. Lou XY, Chen GB, Yan L, Ma JZ, Mangold JE, Zhu J et al (2008). A combinatorial approach to detecting gene-gene and gene-environment interactions in family studies. Am J Hum Genet 83: 457-467.
55. Lou XY, Chen GB, Yan L, Ma JZ, Zhu J, Elston RC et al (2007a). A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. Am J Hum Genet 80: 1125-1137.
56. Lou XY, Ma JZ, Sun D, Payne TJ, Li MD (2007b). Fine mapping of a linkage region on chromosome 17p13 reveals that GABARAP and DLG4 are associated with vulnerability to nicotine dependence in European-Americans. Hum Mol Genet 16: 142-153.
57. Maes HH, Sullivan PF, Bulik CM, Neale MC, Prescott CA, Eaves LJ et al (2004). A twin study of genetic and environmental influences on tobacco initiation, regular tobacco use and nicotine dependence. Psychol Med 34: 1251-1261.
58. Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF (2006). Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 11: 400-409.
59. Martinez D, Gelernter J, Abi-Dargham A, van Dyck CH, Kegeles L, Innis RB et al (2001). The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology 24: 553-560.
60. McKinney EF, Walton RT, Yudkin P, Fuller A, Haldar NA, Mant D et al (2000). Association between polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers. Pharmacogenetics 10: 483-491.
61. Mill J, Asherson P, Browes C, D'Souza U, Craig I (2002). Expression of the dopamine transporter gene is regulated by the 3′ UTR VNTR: evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet 114: 975-979.
62. Miller SA, Dykes DD, Polesky HF (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215.
63. Morton LM, Wang SS, Bergen AW, Chatterjee N, Kvale P, Welch R et al (2006). DRD2 genetic variation in relation to smoking and obesity in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Pharmacogenet Genomics 16: 901-910.
64. Newberg A, Lerman C, Wintering N, Ploessl K, Mozley PD (2007). Dopamine transporter binding in smokers and nonsmokers. Clin Nucl Med 32: 452-455.
65. Nielsen DA, Ji F, Yuferov V, Ho A, Chen A, Levran O et al (2008). Genotype patterns that contribute to increased risk for or protection from developing heroin addiction. Mol Psychiatry 13: 417-428.
66. O'Gara C, Stapleton J, Sutherland G, Guindalini C, Neale B, Breen G et al (2007). Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment. Pharmacogenet Genomics 17: 61-67.
67. Perkins KA, Lerman C, Grottenthaler A, Ciccocioppo MM, Milanak M, Conklin CA et al (2008). Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood. Behav Pharmacol 19: 641-649.
68. Piper ME, McCarthy DE, Baker TB (2006). Assessing tobacco dependence: a guide to measure evaluation and selection. Nicotine Tob Res 8: 339-351.
69. Radloff L (1977). The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1: 385-401.
70. Russell MAH, Peto J, Patel UA (1974). The classification of smoking by factorial structure of motives. J R Stat Soc Ser A 137: 313-346.
71. Sabol SZ, Nelson ML, Fisher C, Gunzerath L, Brody CL, Hu S et al (1999). A genetic association for cigarette smoking behavior. Health Psychol 18: 7-13.
72. Sacchetti P, Brownschidle LA, Granneman JG, Bannon MJ (1999). Characterization of the 50-flanking region of the human dopamine transporter gene. Brain Res Mol Brain Res 74: 167-174.
73. Sacchetti P, Mitchell TR, Granneman JG, Bannon MJ (2001). Nurr1 enhances transcription of the human dopamine transporter gene through a novel mechanism. J Neurochem 76: 1565-1572.
74. Saccone SF, Hinrichs AL, Saccone NL, Chase GA, Konvicka K, Madden PA et al (2007). Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet 16: 36-49.
75. Saucedo-Cardenas O, Quintana-Hau JD, Le WD, Smidt MP, Cox JJ, De Mayo F et al (1998). Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc Natl Acad Sci USA 95: 4013-4018.
76. Schneiter K, Laird N, Corcoran C (2005). Exact family-based association tests for biallelic data. Genet Epidemiol 29: 185-194.
77. Schork NJ, Nath SK, Fallin D, Chakravarti A (2000). Linkage disequilibrium analysis of biallelic DNA markers, human quantitative trait loci, and threshold-defined case and control subjects. Am J Hum Genet 67: 1208-1218.
78. Segman RH, Kanyas K, Karni O, Lerer E, Goltser-Dubner T, Pavlov V et al (2007). Why do young women smoke? IV. Role of genetic variation in the dopamine transporter and lifetime traumatic experience. Am J Med Genet B Neuropsychiatr Genet 144B: 533-540.
79. Sotnikova TD, Beaulieu JM, Gainetdinov RR, Caron MG (2006). Molecular biology, pharmacology and functional role of the plasma membrane dopamine transporter. CNS Neurol Disord Drug Targets 5: 45-56.
80. Staats B, Qi L, Beerman M, Sicotte H, Burdett LA, Packer B et al (2005). Genewindow: an interactive tool for visualization of genomic variation. Nat Genet 37: 109-110.
81. Styn MA, Nukui T, Romkes M, Perkins K, Land SR, Weissfeld JL (2008). The impact of genetic variation in DRD2 and SLC6A3 on smoking cessation in a cohort of participants 1 year after enrollment in a lung cancer screening study. Am J Med Genet B Neuropsychiatr Genet 150B: 254-261.
82. Swan GE, Hudmon KS, Jack LM, Hemberger K, Carmelli D, Khroyan TV et al (2003). Environmental and genetic determinants of tobacco use: methodology for a multidisciplinary, longitudinal family-based investigation. Cancer Epidemiol Biomarkers Prev 12: 994-1005.
83. Swan GE, Jack LM, Valdes AM, Ring HZ, Ton CC, Curry SJ et al (2007). Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR. Health Psychol 26: 361-368.
84. Team RDC (2003). R Foundation for Statistical Computing Vienna, Austria.
85. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP et al (2008). A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452: 638-642.
86. Timberlake DS, Haberstick BC, Lessem JM, Smolen A, Ehringer M, Hewitt JK et al (2006). An association between the DAT1 polymorphism and smoking behavior in young adults from the National Longitudinal Study of Adolescent Health. Health Psychol 25: 190-197.
87. Ton TG, Rossing MA, Bowen DJ, Srinouanprachan S, Wicklund K, Farin FM (2007). Genetic polymorphisms in dopamine-related genes and smoking cessation in women: a prospective cohort study. Behav Brain Funct 3: 22.
88. Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE (2007). Molecular genetics of nicotine dependence and abstinence: whole genome association using 520 000 SNPs. BMC Genet 8: 10.
89. Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE et al (2008). Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry 65: 683-693.
90. van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Staley JK, Laruelle M et al (2005). Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med 46: 745-751.
91. Vandenbergh DJ, Bennett CJ, Grant MD, Strasser AA, O'Connor R, Stauffer RL et al (2002). Smoking status and the human dopamine transporter variable number of tandem repeats (VNTR) polymorphism: failure to replicate and finding that never-smokers may be different. Nicotine Tob Res 4: 333-340.
92. Vandenbergh DJ, Persico AM, Uhl GR (1992). A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs. Brain Res Mol Brain Res 15: 161-166.
93. Vink JM, Smit AB, de Geus EJ, Sullivan P, Willemsen G, Hottenga JJ et al (2009). Genome-wide association study of smoking initiation and current smoking. Am J Hum Genet 84: 367-379.
94. Vink JM, Willemsen G, Beem AL, Boomsma DI (2005). The Fagerstrom test for nicotine dependence in a Dutch sample of daily smokers and ex-smokers. Addict Behav 30: 575-579.
95. Wang X, Ye Y, Zhang H (2006). Family-based association tests for ordinal traits adjusting for covariates. Genet Epidemiol 30: 728-736.
96. Weiss RB, Baker TB, Cannon DS, von Niederhausern A, Dunn DM, Matsunami N et al (2008). A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent nicotine addiction. PLoS Genet 4: e1000125.
97. Yang YK, Yao WJ, Yeh TL, Lee IH, Chen PS, Lu RB et al (2008). Decreased dopamine transporter availability in male smokers - a dual isotope SPECT study. Prog Neuropsychopharmacol Biol Psychiatry 32: 274-279.
98. Zetterstrom RH, Solomin L, Jansson L, Hoffer BJ, Olson L, Perlmann T (1997). Dopamine neuron agenesis in Nurr1-deficient mice. Science 276: 248-250.
99. Zetterstrom RH, Solomin L, Mitsiadis T, Olson L, Perlmann T (1996). Retinoid X receptor heterodimerization and developmental expression distinguish the orphan nuclear receptors NGFI-B, Nurr1, and Nor1. Mol Endocrinol 10: 1656-1666.